Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 12:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Arena Pharmaceuticals Clear all
Completed Phase 2 Interventional Results available

Tolerability, Pharmacokinetics, and Efficacy of APD371 in Participants With Crohn's Disease Experiencing Abdominal Pain

NCT03155945
View directory record Official record
Conditions
Crohn's Disease, Abdominal Pain
Interventions
Olorinab
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
Brandon, Florida • Chicago, Illinois • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Sep 28, 2026, 12:05 PM EDT
Terminated Phase 2 Interventional Results available

Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)

NCT04043455
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Olorinab, Placebo
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
69
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Sep 28, 2026, 12:05 PM EDT
Completed Phase 2 Interventional Results available

Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis

NCT02536404
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Etrasimod, Placebo
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
31
States / cities
Birmingham, Alabama • Dothan, Alabama • Thousand Oaks, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2021 · Synced Sep 28, 2026, 12:05 PM EDT
Completed Phase 3 Interventional Results available

Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

NCT03945188
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Etrasimod, Placebo
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
16 Years to 80 Years
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
67
States / cities
Dothan, Alabama • Sun City, Arizona • Lancaster, California + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Sep 28, 2026, 12:05 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis

NCT04162769
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Etrasimod 1 mg, Etrasimod 2 mg, Etrasimod matching placebo
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
35
States / cities
Tucson, Arizona • Canoga Park, California • Fountain Valley, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Sep 28, 2026, 12:05 PM EDT
Completed Phase 3 Interventional Results available

Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis

NCT03996369
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Etrasimod, Placebo
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
16 Years to 80 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
62
States / cities
Dothan, Alabama • Mobile, Alabama • Sun City, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Sep 28, 2026, 12:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-dose Safety Study of APD916 in Healthy Volunteers

NCT01093508
View directory record Official record
Conditions
Narcolepsy With or Without Cataplexy
Interventions
APD916
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 1, 2010 · Synced Sep 28, 2026, 12:05 PM EDT
Completed Phase 2 Interventional

Subjective Study to Assess the Efficacy of APD125 in Patients With Sleep Maintenance Insomnia

NCT00664664
View directory record Official record
Conditions
Primary Insomnia
Interventions
APD125, Placebo
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
744 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Sep 28, 2026, 12:05 PM EDT
Terminated Phase 1 Interventional

Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome

NCT04655599
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Olorinab, Placebo
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 16, 2021 · Synced Sep 28, 2026, 12:05 PM EDT
Terminated Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis

NCT03155932
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
APD334
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
4
States / cities
Sacramento, California • Houston, Texas • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Sep 28, 2026, 12:05 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis

NCT02447302
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Etrasimod, Placebo
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
30
States / cities
Birmingham, Alabama • Dothan, Alabama • Thousand Oaks, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2021 · Synced Sep 28, 2026, 12:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-Dose Safety Study of APD791 in Healthy Volunteers

NCT00529646
View directory record Official record
Conditions
Healthy
Interventions
APD791
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
19 Years to 45 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 29, 2008 · Synced Sep 28, 2026, 12:05 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation

NCT02044874
View directory record Official record
Conditions
Smoking Cessation
Interventions
APD356-lorcaserin hydrochloride, Placebo
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
31
States / cities
Encino, California • Escondido, California • Los Alamitos, California + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Sep 28, 2026, 12:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple-Dose Study to Assess the Safety, Tolerability, and Steady State Pharmacokinetics of APD791 in Healthy Volunteers

NCT00619931
View directory record Official record
Conditions
Healthy
Interventions
APD791
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
19 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 4, 2022 · Synced Sep 28, 2026, 12:05 PM EDT